HLA-B*5801 test ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 38 | Stevens-Johnson syndrome | 1 |
38. Stevens-Johnson syndrome
Clinical trials : 17 / Drugs : 29 - (DrugBank : 9) / Drug target genes : 15 - Drug target pathways : 101
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03046914 (ClinicalTrials.gov) | February 24, 2016 | 6/2/2017 | HLA-B*5801 Screening to Prevent Allopurinol-induced Severe Cutaneous Adverse Reaction | A Prospective Study to Prove the Usefulness of HLA-B*5801 Screening Test for the Prevention of Allopurinol-induced Severe Cutaneous Adverse Reaction in Patient With Chronic Kidney Disease | Stevens-Johnson Syndrome;Kidney Failure, Chronic | Genetic: HLA-B*5801 test | Seoul National University Hospital | Ministry of Food and Drug Safety, Korea | Recruiting | N/A | N/A | All | 600 | N/A | Korea, Republic of |